ABOUT US

ABOUT US

“There is no one-size-fits-all approach when it comes to fertility care. Every treatment plan should be customized to specifically suit each woman’s body and based on individual needs. I strongly believe that everyone has the right to access fertility care, regardless of their age, ovarian reserve, or financial status. “

— Dr. Jie Deng

Jie Deng, M.D., Ph.D., H.C.L.D., FACOG Medical Director

Dr. Deng is a double trained specialist in both Reproductive Endocrinology and Infertility and Maternal-Fetal Medicine. She is also fully trained as an embryologist and is currently one of a handful of reproductive endocrinologists in the United States to be certified as a High Complexity Laboratory Director in Embryology. Her unique background and expertise with the clinical and embryology laboratory provide Dr. Deng with the extensive skill and knowledge that are necessary in treating challenging fertility problems. She has been actively applying individualized fertility treatment including ‘Mild-IVF’ to her patients and achieved pregnancies in otherwise ‘hopeless cases’.

Education:

Stanford University – Reproductive Endocrinology & Infertility (REI) fellowship

 

Yale University – Maternal Fetal Medicine (MFM) fellowship

 

Detroit Medical Center, Wayne State University – Obstetrics & Gynecology residency

 

Zhongshan University, Guangzhou, China – M.D., Ph.D.

KEY PUBLICATIONS

1.   Deng J, Zhao QY, Behr B, et al. (2021) The impact of fertilization modality to aneuploidy. Fertility & Sterility Report February 2021.

 

2.   Deng J, Hong H, Zhao QY, et al. (2020) Preimplantation genetic testing for aneuploidy in poor ovarian responders with four or fewer eggs retrieved. Journal of Assisted Reproductive Genetics. 37(5): 1147–1154.

 

3.   Deng J, Zhao QY, Cinnioglu C, et al. (2020) The impact of culture conditions on blastocyst formation and aneuploidy rates: a comparison between single-step and sequential media in a large academic practice. Journal of Assisted Reproductive Genetics. 37(1): 161-169.

 

4.   Deng J, Mueller M, Geng T, et al. (2017) H19 lncRNA-induced epigenetic programming of hepatic gluconeogenic gene expression in metformin exposed fetus. H19 lncRNA alters methylation and expression of Hnf4α in the liver of metformin-exposed fetuses. Cell Death Dis. 7;8(12).

 

5.  Deng J, Peng WL, Li J et al. (2006) Successful Preimplantation genetic diagnosis for alpha-and beta-thalassemia in China. Prenatal Diagnosis, 26(11): 1021-1028.

Our specialization
01

Mild IVF

Mild IVF uses a different approach to enable growth of the most potential eggs. Read More
Our specialization
02

PCOS

Hormonal imbalance interferes with the growth and release of eggs from ovaries in PCOS women.Read More
Our specialization
03

Preimplantation Genetic Testing

PGT can identify which embryos have the best potential to develop into a healthy fetus. Read More
Our specialization
04

Diminished Ovarian Reserve

DOR or low AMH does not mean you cannot get pregnant, either naturally or via IVF. Read More

Our
specialization

What we specialize in

Jie Deng, M.D., Ph.D., H.C.L.D., FACOG

Medical Director

Dr. Deng is a double trained specialist in both Reproductive Endocrinology & Infertility (REI) and Maternal-Fetal Medicine (MFM). She had her M.D. and Ph.D. degrees in China, and practiced REI in China before receiving additional training at Yale and Stanford University. When Dr. Deng was in China, she was among the first gynecology reproductive endocrinologists to use preimplantation genetic diagnosis (PGD) in clinical practice, and she achieved the first clinical PGD pregnancy for patients with alpha-thalassemia in the country in 2005.

Introduction

Dr. Deng relocated to the United States in 2008 where she was awarded a California Institute of Regenerative Medicine research Grant and worked in the field of stem cell research at University of California in San Diego. Subsequently, Dr. Deng completed her residency in Obstetrics and Gynecology at Detroit Medical Center, Wayne State University.

After residency she was trained and worked as a Maternal-fetal Medicine (MFM) specialist at Yale University. The experience in the MFM field provided Dr. Deng vast special knowledge and skills in high-risk pregnancy care, which attracted many advanced age high risk infertility patients. When Dr. Deng was at Stanford University REI fellowship program, she observed limitations of conventional IVF in many women, and she has been actively applying individualized fertility treatment including ‘Mild-IVF’ to her patients and achieved pregnancies in otherwise ‘hopeless cases’.

Dr. Deng is also fully trained as an embryologist and is currently one of a handful of reproductive endocrinologists in the United States to be certified as a High Complexity Lab Director (H.C.L.D.) in Embryology. Her unique background and expertise with the clinical and embryology laboratory provide Dr. Deng with the extensive skill and knowledge that are necessary in treating challenging fertility cases.

Dr. Deng is a physician scientist. She published a variety of peer-reviewed articles in the fields of reproductive health, genetics, epigenetics, and stem cells in journals such as Nature Medicine, Nature Genetics, Nature Methods, Fertility & Sterility, Journal of Assisted Reproduction and Genetics, Molecular Human Reproduction, Prenatal Diagnosis, Genome Research, Cell Stem Cell and Molecular Cells.

Education

Fellowship – Reproductive Endocrinology & Infertility, Stanford Reproductive & Fertility Health, Sunnyvale, CA USA

Fellowship – Maternal Fetal Medicine, Yale New Haven Hospital, New Haven, CT USA

Residency – Obstetrics and Gynecology, Detroit Medical Center, Wayne state university, Detroit, MI USA

Research Fellow – California Institute of Regenerative Medicine (CIRM), Bioengineering

Department, University of California in San Diego, La Jolla, CA USA

M.D., Ph.D. – Zhongshan University (Sun Yat-Sen University of Medical Sciences), Guangzhou, China